<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170517</url>
  </required_header>
  <id_info>
    <org_study_id>ProFETStudy</org_study_id>
    <nct_id>NCT04170517</nct_id>
  </id_info>
  <brief_title>Serum Progesterone Levels on the Day of Frozen Embryo Transfer (FET) and Pregnancy Outcomes</brief_title>
  <acronym>ProFET</acronym>
  <official_title>Serum Progesterone Levels on the Day of Frozen Embryo Transfer (FET) and Pregnancy Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CARE Fertility UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CARE Fertility UK</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frozen embryo transfer (FET) cycles have become more common in recent years due to a push
      towards elective single embryo transfer (SET). While it is known that progesterone
      supplementation during the luteal phase improves clinical pregnancy rates, there is a paucity
      of prospective data on the impact of serum progesterone levels on pregnancy outcomes in FET
      cycles. This multicentre prospective cohort study aims to investigate the association between
      serum progesterone levels on the day of FET and pregnancy outcomes, and to determine a serum
      progesterone cut-off value above which clinical pregnancy and live birth are more likely to
      occur. Women undergoing ART-FET cycles at CARE Fertility clinics in the UK will be recruited
      and their serum progesterone measured on the day of frozen embryo transfer. Follow-up data
      will be stored in electronic patient records and analysed to determine whether a low serum
      progesterone level on the day of FET adversely affects ART outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate per participant</measure>
    <time_frame>18 months</time_frame>
    <description>Birth of a live fetus at 24 or more weeks of gestational age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate per participant</measure>
    <time_frame>18 months</time_frame>
    <description>Any clinical pregnancy lost before week 12 of gestation per participant (number of events/number of participants, %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rates per participant</measure>
    <time_frame>18 months</time_frame>
    <description>Number of gestational sacs seen in a 2D transvaginal ultrasound scan divided by the number of embryos transferred per patient (number of events/number of embryos transferred, %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate per participant</measure>
    <time_frame>18 months</time_frame>
    <description>Positive pregnancy test following embryo transfer per participant (number of events/number of participants, %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate per participant</measure>
    <time_frame>18 months</time_frame>
    <description>Presence of at least one gestational sac on ultrasound (number of events/number of participants, %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic pregnancy rate per participant</measure>
    <time_frame>18 months</time_frame>
    <description>number of events/number of participants, %</description>
  </secondary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Infertility</condition>
  <condition>Infertility, Female</condition>
  <condition>IVF</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measurement of serum progesterone on the day of FET</intervention_name>
    <description>Measurement of serum progesterone on the day of FET</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum progesterone will be measured from consenting participants on the day of frozen embryo
      transfer.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All women undergoing ART with FET.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women undergoing ART with FET.

        Exclusion Criteria:

          -  None. We aim to study the &quot;every day&quot; patient undergoing FET, and for this we intend
             to keep the population of the study as unselected as possible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arri Coomarasamy, MBChB MD FRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>CARE Fertility UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Melo, MD MSc MRCOG</last_name>
    <phone>00441214559334</phone>
    <email>pedro.melo@carefertility.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CARE Fertility Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Melo, MD</last_name>
      <phone>0121 455 9334</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared with other researchers. Any IPD will be confined to the purposes of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

